Pancreatic Cancer Research

ResearcherNew York UniversityActive in the last 2 years

Howard S. Höchster

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-9893-1529; OpenAlex author ID A5015750678, A5039477855. Sources: ClinicalTrials.gov.

Their work

Papers
18 (first author 3, last author 6)
Trials
2 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
68
Papers, trials and grants by year

1997: 1 trial · 1998: none · 1999: none · 2000: none · 2001: none · 2002: none · 2003: none · 2004: none · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: none · 2012: none · 2013: 1 paper · 2014: none · 2015: 2 papers · 2016: 1 paper · 2017: 3 papers · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 3 papers · 2022: 1 paper, 1 trial · 2023: 1 paper · 2024: none · 2025: none · 2026: 2 papers

Papers 18

  1. Global cooperation and localized pancreatic cancer. First author DOI 10.1093/jnci/djag086↗
  2. Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinom… Co-author DOI 10.3390/cancers18030507↗
  3. Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic… Last author DOI 10.1002/cam4.6621↗
  4. Bias and Pancreatic Cancer Reporting. Co-author DOI 10.1093/jnci/djac020↗
  5. Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial. Last author DOI 10.1001/jamaoncol.2020.7328↗
  6. Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: … Last author DOI 10.1158/1078-0432.ccr-21-1789↗
  7. Outcomes of patients with borderline resectable and resectable pancreatic adenocarcinoma treated with neoadjuvant three-week course chemoradiotherapy using cap… Co-author DOI 10.21037/jgo-21-503↗
  8. Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectabl… Last author DOI 10.1097/sla.0000000000004155↗
  9. Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer. First author DOI 10.1158/1078-0432.ccr-20-0099↗
  10. Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenoc… Last author DOI 10.1200/jco.18.01295↗
  11. Can we downstage locally advanced pancreatic cancer to resectable? A phase I/II study of induction oxaliplatin and 5-FU chemoradiation. Co-author DOI 10.21037/jgo.2017.10.04↗
  12. Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomize… Last author DOI 10.1001/jamaoncol.2016.5383↗
  13. Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor. Co-author DOI 10.1158/1535-7163.mct-16-0794↗
  14. A Long-Term Survivor of Metastatic Pancreatic Adenocarcinoma: Free of Recurrence 12 Years After Treatment of Oligometastatic Disease. Co-author DOI 10.7759/cureus.1007↗
  15. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Co-author DOI 10.1038/bjc.2016.45↗
  16. Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/meta… Co-author DOI 10.1093/annonc/mdu581↗
  17. Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity. First author DOI 10.1186/s40164-015-0025-y↗
  18. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Co-author DOI 10.1007/s12032-012-0361-2↗

Trials 2

  1. Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer Principal investigator NCT05296421↗
  2. Combination Chemotherapy Followed by Chemotherapy and Radiation Therapy and/or Surgery in Treating Patients Who Have Pancreatic Cancer Study chair NCT00003332↗

Closest collaborators

The 25 strongest of 68 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elena Gabriela Chiorean · 7 shared papers, 2019–2026 · strength 0.89
  2. Brett Logan Ecker · 1 shared paper, 2026 · strength 0.63
  3. Philip A. Philip · 5 shared papers, 2017–2021 · strength 0.47
  4. H. Richard Alexander · 2 shared papers, 2021–2022 · strength 0.44
  5. Andrew M. Lowy · 4 shared papers, 2017–2021 · strength 0.39
  6. Sunil R. Hingorani · 2 shared papers, 2019–2026 · strength 0.31
  7. Andrew Eugene Hendifar · 2 shared papers, 2017–2026 · strength 0.29
  8. Andrea Wang‐Gillam · 3 shared papers, 2017–2021 · strength 0.28
  9. Jill Lacy · 4 shared papers, 2013–2019 · strength 0.24
  10. Martin C. Whittle · 1 shared paper, 2026 · strength 0.23
  11. Ben George · 1 shared paper, 2026 · strength 0.23
  12. Andrew L. Coveler · 1 shared paper, 2026 · strength 0.23
  13. Sita Kugel · 1 shared paper, 2026 · strength 0.23
  14. Tomislav Dragovich · 1 shared paper, 2026 · strength 0.23
  15. Rachael Ann Safyan · 1 shared paper, 2026 · strength 0.23
  16. David Bing Zhen · 1 shared paper, 2026 · strength 0.23
  17. Davendra P. S. Sohal · 2 shared papers, 2020–2021 · strength 0.22
  18. Muhammad Shaalan Beg · 2 shared papers, 2020–2021 · strength 0.22
  19. Namita Sharma Gandhi · 2 shared papers, 2020–2021 · strength 0.22
  20. Talia Golan · 1 shared paper, 2023 · strength 0.17
  21. Jean‐Frédéric Blanc · 1 shared paper, 2023 · strength 0.17
  22. Joan Maurel · 1 shared paper, 2023 · strength 0.17
  23. Marc Peeters · 1 shared paper, 2023 · strength 0.17
  24. Chung‐Pin Li · 1 shared paper, 2023 · strength 0.17
  25. Vincent J. Picozzi · 1 shared paper, 2023 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.